Brief: Galectin Therapeutics Receives FDA Approval To Proceed With Combination Immunotherapy Trial In Head And Neck Cancer
12/10/2022 13:09
Oct 12 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS RECEIVES FDA APPROVAL TO PROCEED
WITH
COMBINATION IMMUNOTHERAPY TRIAL IN HEAD AND NECK CANCER
Source text for Eikon: ID:nGNX9ltHqp
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study